

Investment Banking Update

\$149 MILLION

May 21, 2019

FOLLOW-ON OFFERING



The undersigned served as
Co-Manager on the offering

Stephens Inc.

Transaction Details

- On May 21, 2019, NeoGenomics, Inc. ("NEO" or the "Company") announced the pricing of an underwritten public offering of 7,000,000 primary shares of its common stock at a price to the public of \$21.25 per share
 - The Company also granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of NEO common stock
- NeoGenomics intends to use net proceeds for general corporate purposes
 - NeoGenomics may use a portion of the net proceeds to acquire or invest in complementary businesses and technologies, although there are no current commitments or agreements with respect to any such transactions
- Stephens Inc. served as Co-Manager on the offering

According to the Company's Press Release

NeoGenomics, Inc. (Nasdaq: NEO) specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Sources: Company filings and press release.

This material has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. Information included in the material was obtained from external sources which we consider reliable, but we have not independently verified such information and do not guarantee that it is accurate or complete. Such information is believed to be accurate on the date of issuance of the material. No subsequent publication or distribution of this material shall mean or imply that any such information or opinion remains current at any time after the stated date of the material. We do not undertake to advise you of any changes in any such information or opinion. Additional information is available upon request.

The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from Stephens Inc.'s Equity Syndicate Desk, at Stephens Inc., 111 Center Street, Little Rock, AR 72201, ATTN: Equity Syndicate Desk, or from the Securities and Exchange Commission's website at www.sec.gov at the following link:

<https://www.sec.gov/Archives/edgar/data/1077183/000107718319000082/prospectussupplementpricing.htm>. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to the notice of its acceptance given after the effective date.